Company / Operating Cash Flow
Nurix Therapeutics, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$249.5M
FY2025
5-year range
-$249.5M / $601.0K
FY2021-FY2025
Trend
-44.5%
vs FY2024
Sector context
#183 of 216
Health Care
What the data says
Nurix Therapeutics, Inc.'s operating cash flow of -$249M is lower than 85% of companies in the Health Care sector (FY2025). Operating Cash Flow has fluctuated over the past 7 years, ranging from -$249M in FY2025 to $601,000 in FY2021.
Based on SEC 10-K filings.
-$249M in FY2025.
Declined from -$81M to -$249M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 216This company -$249.5M Sector average $659.0M
▼
-137.9% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 44.5% year-over-year.
- Ranks #183 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.35 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$249.5M | -44.5% |
| FY2024 | -$172.6M | -112.1% |
| FY2023 | -$81.4M | +3.6% |
| FY2022 | -$84.4M | -14137.4% |
| FY2021 | $601.0K | +851.2% |
| FY2020 | -$80.0K | -113.3% |
| FY2019 | $601.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026